# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy ...
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global ...
UCB announces a $680 million strategic divestment deal in China, selling its neurology and allergy business to CBC Group and Mu...
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexic...
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Ther...
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG)...
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstandin...